| Literature DB >> 30056385 |
Michael Reddington1, Stephen J Walters2, Judith Cohen3, Susan K Baxter4, Ashley Cole5.
Abstract
OBJECTIVE: To investigate the feasibility of undertaking a definitive randomised controlled trial (RCT).Entities:
Keywords: back pain; musculoskeletal disorders; spine
Mesh:
Year: 2018 PMID: 30056385 PMCID: PMC6067394 DOI: 10.1136/bmjopen-2018-021631
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1POLAR Consolidated Standards of Reporting Trials flow chart.
Baseline characteristics of POLAR participants
| Early intervention physiotherapy | Usual care | Total | |||||||
| N | % | N | % | N | % | ||||
| Female | 21 | 50 | 18 | 47 | 39 | 49 | |||
| White British | 38 | 90 | 33 | 87 | 71 | 89 | |||
*Three missing values.
†Time between randomisation and first scheduled treatment session.
BMI, body mass index; ODI, Oswestry Disability Index; VAS, Visual Analogue Scale, EQ-5D-5L, EuroQol-5 Dimensions.
Figure 2Leg pain and ODI scores across groups. ODI, Oswestry Disability Index.
Descriptive statistics for outcome measures at each time point
| Outcome | Baseline | 6 weeks | 12 weeks | 26 weeks | Area under the response curve (AUC) | ||||||||
| Usual care n=38 | Early intervention physiotherapy n=42 | Usual care n=35 | Early intervention physiotherapy n=38 | Usual Care n=32 | Early intervention physiotherapy n=36 | Usual Care n=32 | Early intervention physiotherapy n=36 | Usual care n=32 | Early intervention physiotherapy n=36 | Difference 95 | |||
| Mean | Lower | Upper | |||||||||||
| ODI* (SD) | 45.2 (17.4) | 44.6 (19.5) | 29.1 (16.1) | 24.0 (18.7) | 16.8 (19.2) | 16.0 (19.0) | 8.8 (11.3) | 11.3 (15.5) | 16.6 (11.4) | 16.0 (14.0) | −0.6 | −6.8 | 5.6 |
| VAS back† (SD) | 6.0 (2.6) | 5.4 (3.3) | 4.6 (2.7) | 3.7 (2.6) | 3.1 (2.5) | 2.6 (2.5) | 2.1 (2.1) | 2.7 (2.2) | 1.8 (0.8) | 1.5 (1.0) | −0.3 | −0.7 | 0.1 |
| VAS leg† (SD) | 6.9 (2.3) | 7.2 (1.8) | 5.2 (2.9) | 4.1 (3.0) | 2.6 (2.9) | 2.0 (2.5) | 0.9 (2.2) | 1.6 (2.2) | 1.7 (0.9) | 1.5 (1.0) | −0.2 | −0.6 | 0.3 |
| EQ-5D5L‡VAS (SD) | 64.6 (18.9) | 63.8 (20.6) | 68.9 (16.4 | 72.7 (17.7) | 73.2 (22.9) | 79.6 (17.5) | 81.7 (12) | 79.6 (16.3) | 36.8 (7.1) | 38.1 (7.8) | 1.4 | −2.2 | 5.0 |
| EQ-5D-5L§ utility score (SD) | 0.52 (0.25) | 0.44 (0.29) | 0.7 (0.26) | 0.74 (0.22) | 0.83 (0.23) | 0.85 (0.22) | 0.92 (0.12) | 0.86 (0.19) | 0.39 (0.09) | 0.39 (0.10) | 0.00 | −0.05 | 0.04 |
*Oswestry Disability Index (ODI) 0–100, higher score=higher level of self-rated disability. For the ODI, a larger AUC represents a greater level of disability over the 26 weeks. A negative difference means the early intervention physiotherapy group has the better outcome (lower levels of disability) over the 26 weeks follow-up.
†VAS 0–10, higher score=higher self-report pain. For the VAS back pain and leg pain outcomes, a larger AUC represents a higher level of pain over the 26 weeks. A negative difference means the early intervention physiotherapy group has the better outcome (lower levels of pain) over the 26 weeks follow-up.
‡EQ-5D-5L VAS score, 0–100, self-rated health. the higher the score, the better the quality of life. For the EQ-5D-5L VAS score, a larger AUC represents a higher level of quality of life over the 26 weeks. A positive difference means the early intervention physiotherapy group has the better outcome (higher levels of quality of life) over the 26 weeks follow-up.
§EQ-5D-5L utility score, −0.6 to 1.00 with a higher score representing better quality of life. For the EQ-5D-5L utility score, a larger AUC represents a higher level of quality of life over the 26 weeks. A positive difference means the early intervention physiotherapy group has the better outcome (higher levels of quality of life) over the 26 weeks follow-up.
VAS, Visual Analogue Scale.
Intervention domains and components frequency table
| Domain | No of participants receiving component n=69 | Method of assessment | Treatment options | Frequency of component used | % |
| Psychological barriers to recovery | 47 (68%) | Keele STarT Back | 1. Treatment of kinesiophobia with graded exposure, education and movement re-education | 16 | 1.3 |
| 2. Treatment of hypervigilance with education, distraction and desensitisation | 17 | 1.4 | |||
| 3. Treatment of faulty beliefs about pain, LRS, treatment and/or prognosis with education and self-management strategies | 38 | 3.2 | |||
| 4. Treatment of Iatrogenic beliefs and corresponding avoidance behaviours with education and movement re-education | 3 | 0.2 | |||
| 5. Treatment of aspects of work as a barrier to recovery and treatment with ergonomic advice and practice | 15 | 1.2 | |||
| 6. Identification of financial barriers to recovery and signposting, for example, debt management | 15 | 1.2 | |||
| 7. Identification of emotional barriers to recovery and signposting to appropriate therapy, for example, GP/psychology | 57 | 4.7 | |||
| Neurological | 39 (58%) | Clinical assessment | 1. Neural interface mobilisation | 98 | 8.1 |
| 2. Functional neurological movement re-education | 7 | 0.6 | |||
| Movement restriction | 59 (86%) | Clinical assessment | 1. Flexion mobilisation (grades 2–4) | 68 | 5.6 |
| 2. Side flexion mobilisation (grades 2–4) | 5 | 0.4 | |||
| 3. Extension mobilisation (grades 2–4) | 15 | 1.2 | |||
| 4. Rotation mobilisation (grades 2–4) | 41 | 3.4 | |||
| 5. Flexion+side flexion mobilisation (grades 2–4) | 11 | 0.9 | |||
| 6. Flexion+side+flexion+rotation mobilisation (grades 2–4) | 62 | 5.2 | |||
| 7. Extension+side flexion mobilisation (grades 2–4) | 0 | 0 | |||
| 8. Manipulation (grade 5) | 0 | 0 | |||
| 9. Seated mobilisation with movement (MWM) | 16 | 1.3 | |||
| 10. Standing MWM | 16 | 1.3 | |||
| 11. Mobilisation into functional position | 14 | 1.2 | |||
| 12. Muscle stretches | 61 | 5.1 | |||
| 13. Functional movement re-education | 7 | 0.6 | |||
| Understanding | 66 (96%) | 1. Management of erroneous believes relating to LRS provide education to help eradicate these beliefs | 57 | 4.7 | |
| 2. Pacing behaviours | 53 | 4.4 | |||
| 3. Goal attainment | 58 | 4.8 | |||
| 4. Health Promotion | 80 | 6.6 | |||
| 5. Identification and treatment of central sensitisation-liaison with GP/pain clinic | 8 | 0.7 | |||
| 6. Identification and treatment of peripheral sensitisation-liaison with GP/pain clinic | 7 | 0.6 | |||
| Conditioning | 63 (91%) | Self-assessment answers, clinical interview and history | 1. Cardiovascular and conditioning exercise relevant to patients’ goals | 83 | 6.9 |
| 2. Function-specific stretches | 39 | 3.2 | |||
| 3. Function-specific strengthening | 62 | 5.2 | |||
| 4. Ergonomic advice | 14 | 1.2 | |||
| 5. Ergonomic practice | 6 | 0.5 | |||
| 6. Group exercise | 0 | 0.0 | |||
| 7. Perturbation training | 7 | 0.6 | |||
| Movement control | 33 (48%) | Clinical assessment | 1. Sagittal plane control in functional positions relevant to patients’ problems/goals | 24 | 2.0 |
| 2. Coronal plane control in functional positions relevant to patients’ problems/goals | 15 | 1.2 | |||
| 3. Axial plane control in functional positions relevant to patients’ problems/goals | 1 | 0.1 | |||
| 4. Multiplanar control in functional positions relevant to patients’ problems/goals | 6 | 0.5 | |||
| 5. Movement re-education in functional positions relevant to patients’ problems/goals | 18 | 1.5 | |||
| Pain | 52 (75%) | ODI | 1. Analgesic review and advice in liaison with GP/Pharmacist | 23 | 1.9 |
| 2. Pain education | 60 | 5.0 | |||
| 3. Pain coping strategies | 20 | 1.7 | |||
| 4. Fear reduction intervention in liaison with psychologist/pain clinic | 12 | 1.0 | |||
| 5. Stress reduction intervention in liaison with psychologist/pain clinic | 32 | 2.7 | |||
| Totals | 1267 | 99.8%* | |||
*0.2% missing data, two treatment episodes where components not attributed.
GP, general practitioner; LRS, lumbar radicular syndrome; ODI, Oswestry Disability Index; VAS, Visual Analogue Scale.
Sample sizes for main randomised controlled trial for a range of target mean differences with a primary outcome of the Oswestry Disability Index score at 26 weeks postrandomisation
| Significance level (%) | Power (%) | SD | Target mean difference | Standardised effect size | No in each group | Total sample size (N) | Total sample size drop-out | |
| 15% | 20% | |||||||
| 5 | 90 | 16 | 2 | 0.13 | 1346 | 2692 | 3168 | 3366 |
| 5 | 90 | 16 | 2.5 | 0.16 | 862 | 1724 | 2030 | 2156 |
| 5 | 90 | 16 | 3 | 0.19 | 599 | 1198 | 1410 | 1498 |
| 5 | 90 | 16 | 3.5 | 0.22 | 441 | 882 | 1038 | 1104 |
| 5 | 90 | 16 | 4 | 0.25 | 338 | 676 | 796 | 846 |
| 5 | 90 | 16 | 4.5 | 0.28 | 267 | 534 | 630 | 668 |
| 5 | 90 | 16 | 5 | 0.31 | 217 | 434 | 512 | 544 |
| 5 | 90 | 16 | 5.5 | 0.34 | 179 | 358 | 422 | 448 |
| 5 | 90 | 16 | 6 | 0.38 | 151 | 302 | 356 | 378 |
| 5 | 90 | 16 | 6.5 | 0.41 | 129 | 258 | 304 | 324 |
| 5 | 90 | 16 | 7 | 0.44 | 111 | 222 | 262 | 278 |
| 5 | 90 | 16 | 7.5 | 0.47 | 97 | 194 | 230 | 244 |
| 5 | 90 | 16 | 8 | 0.50 | 86 | 172 | 204 | 216 |
| 5 | 90 | 16 | 8.5 | 0.53 | 76 | 152 | 180 | 190 |
| 5 | 90 | 16 | 9 | 0.56 | 68 | 136 | 160 | 170 |
| 5 | 90 | 16 | 9.5 | 0.59 | 61 | 122 | 144 | 154 |
| 5 | 90 | 16 | 10 | 0.63 | 55 | 110 | 130 | 138 |